Callan Capital LLC Buys 178 Shares of Zoetis Inc. (NYSE:ZTS)

Callan Capital LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 7.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,688 shares of the company’s stock after purchasing an additional 178 shares during the period. Callan Capital LLC’s holdings in Zoetis were worth $466,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of ZTS. Aveo Capital Partners LLC purchased a new position in Zoetis in the 4th quarter valued at approximately $225,000. Gryphon Financial Partners LLC lifted its holdings in shares of Zoetis by 11.8% in the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after buying an additional 322 shares in the last quarter. Jump Financial LLC purchased a new position in Zoetis during the fourth quarter valued at approximately $339,000. TrinityPoint Wealth LLC increased its holdings in Zoetis by 0.3% during the 4th quarter. TrinityPoint Wealth LLC now owns 22,319 shares of the company’s stock worth $4,405,000 after acquiring an additional 73 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Zoetis by 8.9% in the 4th quarter. Franklin Resources Inc. now owns 161,489 shares of the company’s stock worth $31,873,000 after purchasing an additional 13,236 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Zoetis stock opened at $192.73 on Friday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The firm has a market cap of $87.94 billion, a P/E ratio of 37.13, a P/E/G ratio of 2.98 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The firm has a 50-day moving average of $184.70 and a 200-day moving average of $174.47.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.41 earnings per share. Sell-side analysts expect that Zoetis Inc. will post 5.84 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on ZTS shares. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $220.38.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.